Expression of DNA damage response molecules PARP1, γH2AX, BRCA1, and BRCA2 predicts poor survival of breast carcinoma patients

Translational Oncology

Volumn 8, Issue 4, 2015, Pages 239-249

  Park, See Hyoung ^a   Noh, Sang Jae ^b   Kim, Kyoung Min ^b   Bae, Jun Sang ^b   Kwon, Keun Sang ^b   Jung, Sung Hoo ^b   Kim, Jung Ryul ^b   Lee, Ho ^b   Chung, Myoung Ja ^b   Moon, Woo Sung ^b   Kang, Myoung Jae ^b   Jang, Kyu Yun ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; HISTONE H2AX; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; DNA DAMAGE; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84940206128     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.04.004     Document Type: Article

References (51)

1. Carey LA and Sharpless NE (2011). PARP and cancer—if it's broke, don't fix it. N Engl J Med 364, 277–279.
2. Krishnakumar R and Kraus WL (2010). The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39, 8–24.
3. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, and Pommier Y (2010). Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16, 4532–4542.
4. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, and Sherman BM (2010). Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1, 812–821.
5. Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, and Ramírez-Merino N (2012). Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 23, 1156–1164.
6. Gan A, Green AR, Nolan CC, Martin S, and Deen S (2013). Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian highgrade serous carcinoma; association with patient survival. Hum Pathol 44, 1638–1647.
7. Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, Scalvenzi M, Salvatore G, Fabbrocini G, and Molea G, et al (2005). Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 36, 724–731.
8. Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, Bosco P, Castiglione R, and Salemi M (2012). PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem 56, e9.
9. Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, and Kirkby NF (2013). Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8, 65.
10. Chow JP, Man WY, Mao M, Chen H, Cheung F, Nicholls J, Tsao SW, Li Lung M, and Poon RY (2013). PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol Cancer Ther 12, 2517–2528.
11. Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, and Nocentini G, et al (2008). Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer 44, 1302–1314.
12. García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, and Eroles P (2014). Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. Eur J Cancer 50, 2725–2734.
13. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, and Schmutzler RK (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244.
14. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, and Pommier Y (2008). γH2AX and cancer. Nat Rev Cancer 8, 957–967.
15. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, and Bonner WM (2009). H2AX: functional roles and potential applications. Chromosoma 118, 683–692.
16. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, and Bonner W (2002). Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 12, 162–169.
17. Kinner A, Wu W, Staudt C, and Iliakis G (2008). γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36, 5678–5694.
18. Podhorecka M, Skladanowski A, and Bozko P (2010). H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids, 920161.
19. Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US, and Bonner WM (2011). Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. Aging (Albany NY) 3, 168–174.
20. Rothkamm K and Lobrich M (2003). Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A 100, 5057–5062.
21. Nagelkerke A, van Kuijk SJ, Sweep FC, Nagtegaal ID, Hoogerbrugge N, Martens JW, Timmermans MA, van Laarhoven HW, Bussink J, and Span PN (2011). Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer. Radiother Oncol 101, 39–45.
22. Mhawech-Fauceglia P, Wang D, Kim G, Sharifian M, Chen X, Liu Q, Lin YG, Liu S, and Pejovic T (2014). Expression of DNA repair proteins in endometrial cancer predicts disease outcome. Gynecol Oncol 132, 593–598.
23. Brunner AH, Hinterholzer S, Riss P, Heinze G, Weiss K, and Brustmann H (2011). Expression of γ-H2AX in endometrial carcinomas: an immunohistochemical study with p53. Gynecol Oncol 121, 206–211.
24. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, and Martin OA (2012). Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 327, 123–133.
25. Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, Friedlander M, and Carmichael J (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 27, CRA501.
26. Isakoff S, Overmoyer B, Tung N, Gelman R, Giranda V, Bernhard K, Habin K, Ellisen L, Winer E, and Goss P (2010). A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28, 1019.
27. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, and Gilks B, et al (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12, 852–861.
28. Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, and Soslow RA (2013). BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 37, 138–146.
29. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, and Van de Vijver MJ (2012). WHO Classification of Tumours of the Breast. Lyon, France: IARC; 2012.
30. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, and Trotti A (2010). AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
31. Allred D, Harvey JM, Berardo M, and Clark GM (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11, 155–168.
32. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Yu TK, Kim KM, Park HS, Lee J-H, and Moon WS (2013). Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One 8, e74738.
33. Noh SJ, Bae JS, Jamiyandorj U, Park HS, Kwon KS, Jung SH, Youn HJ, Lee H, Park BH, and Chung MJ, et al (2013). Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients. BMC Cancer 13, 516.
34. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, and Chung MJ, et al (2013). Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8, e82870.
35. Kang MJ, Kim KM, Bae JS, Park HS, Lee H, Chung MJ, Moon WS, Lee DG, and Jang KY (2013). Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol 6, 282–289.
36. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, and Fitzgibbons P, et al (2014). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138, 241–256.
37. Mylona E, Melissaris S, Nomikos A, Theohari I, Giannopoulou I, Tzelepis K, and Nakopoulou L (2014). Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas. Pathol Res Pract 210, 533–540.
38. Bertram C and Hass R (2008). Cellular responses to reactive oxygen species-induced DNA damage and aging. Biol Chem 389, 211–220.
39. Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, and Sakamuro D (2011). c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 4, ra19.
40. Yan J and Tang D (2014). Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response. Exp Cell Res 328, 132–142.
41. Donizy P, Pietrzyk G, Halon A, Kozyra C, Gansukh T, Lage H, Surowiak P, and Matkowski R (2014). Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node negative early breast cancer: 15-year follow-up. Oncol Rep 31, 1777–1787.
42. Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, André F, Turner NC, Symmans WF, and Hortobágyi GN (2013). DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 18, 1063–1073.
43. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder Stephenson L, Salerno G, Conway TA, and Lynch HT (1996). Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77, 697–709.
44. Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, and Loman N (2014). Long-term prognosis of early-onset breast cancer in a populationbased cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat 144, 133–142.
45. Verhoog L, Brekelmans C, Seynaeve C, Van den Bosch L, Dahmen G, Van Geel A, Tilanus-Linthorst M, Bartels C, Wagner A, and Van den Ouweland A (1998). Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351, 316–321.
46. Huzarski T, Byrski T, Gronwald J, Górski B, Domagała P, Cybulski C, Oszurek O, Szwiec M, Gugała K, and Stawicka M (2013). Ten-year survival in patients With BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31, 3191–3196.
47. Cho D, Park H, Park SH, Kim K, Chung M, Moon W, Kang M, and Jang K (2015). The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma. J Ovarian Res 8, 2.
48. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, and McGuffog L, et al (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307, 382–390.
49. Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, and Schuh A, et al (2014). A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer 14, 983.
50. Wiedemeyer WR, Beach JA, and Karlan BY (2014). Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol 4, 34.
51. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, and Schutte M (2006). BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66, 41–45.